Gelonghui, December 20 | Changchun Hi-Tech (000661.SZ) announced that the holding subsidiary of the company, Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as “Baike Biotech”), received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for the herpes simplex virus mRNA vaccine type 2 was approved. Genital herpes caused by herpes simplex virus type 2 infection is an infectious disease with sexual activity as the main transmission route. It is prone to infection, recurrent episodes, and has no effective cure, and has become a serious public health problem. In order to prevent the occurrence of genital herpes, many biomedical companies have continued to work on the development of herpes simplex virus vaccines.

Baike Biotech's clinically approved herpes simplex virus vaccine line was jointly declared by Zhuhai Levanda Biotechnology Co., Ltd. (Baike Biotech is the approval holder). The vaccine is a multi-component vaccine that can simultaneously induce humoral immune response and cellular immune response, and uses mRNA technology routes to further enhance cellular immune response, which increases the possibility of successful vaccine development compared with traditional technical routes.

Up to now, no relevant vaccine products have been successfully developed and marketed in the world. If Baig Biotech's type II herpes simplex virus mRNA vaccine can be successfully developed, it will further enrich the company's product pipeline and better meet market needs.